WO1996040260A3 - Immunotoxins specific for cd80 and cd86 expressing cells - Google Patents

Immunotoxins specific for cd80 and cd86 expressing cells Download PDF

Info

Publication number
WO1996040260A3
WO1996040260A3 PCT/EP1996/002492 EP9602492W WO9640260A3 WO 1996040260 A3 WO1996040260 A3 WO 1996040260A3 EP 9602492 W EP9602492 W EP 9602492W WO 9640260 A3 WO9640260 A3 WO 9640260A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
relates
expressing cells
immunotoxin
human
Prior art date
Application number
PCT/EP1996/002492
Other languages
French (fr)
Other versions
WO1996040260A2 (en
Inventor
Boer Mark De
Gast G C De
Original Assignee
Innogenetics Nv
Boer Mark De
Gast G C De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv, Boer Mark De, Gast G C De filed Critical Innogenetics Nv
Priority to US08/973,377 priority Critical patent/US6071519A/en
Priority to JP9500165A priority patent/JPH11506915A/en
Priority to AU63016/96A priority patent/AU709988B2/en
Priority to EP96921952A priority patent/EP0831917A2/en
Publication of WO1996040260A2 publication Critical patent/WO1996040260A2/en
Publication of WO1996040260A3 publication Critical patent/WO1996040260A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The present invention relates to compositions and methods for treating diseases of the immune system. More particularly, the invention relates to an immunotoxin molecule comprising an antibody specific for human CD80 or CD86 antigen located on the surface of a human cell, coupled to a toxin molecule or active fragment thereof, wherein the binding of the immunotoxin to the CD80 or CD86 antigen results in the killing of the CD80 or CD86 expressing cell. In particular, this invention relates to methods of preventing allograft rejection and methods for treating autoimmune diseases and various malignancies of lymphoid origin.
PCT/EP1996/002492 1995-06-07 1996-06-07 Immunotoxins specific for cd80 and cd86 expressing cells WO1996040260A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/973,377 US6071519A (en) 1995-06-07 1996-06-07 Immunotoxins specific for CD86 expressing cells
JP9500165A JPH11506915A (en) 1995-06-07 1996-06-07 Immunotoxins specific for CD80 and CD86 expressing cells
AU63016/96A AU709988B2 (en) 1995-06-07 1996-06-07 Immunotoxins specific for CD80 and CD86 expressing cells
EP96921952A EP0831917A2 (en) 1995-06-07 1996-06-07 Immunotoxins specific for cd80 and cd86 expressing cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95870066.8 1995-06-07
EP95870066 1995-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/373,474 Division US6346248B1 (en) 1995-06-07 1999-08-12 Methods of treating autoimmune diseases with a CD86-specific immunotoxin

Publications (2)

Publication Number Publication Date
WO1996040260A2 WO1996040260A2 (en) 1996-12-19
WO1996040260A3 true WO1996040260A3 (en) 1997-02-20

Family

ID=8222136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002492 WO1996040260A2 (en) 1995-06-07 1996-06-07 Immunotoxins specific for cd80 and cd86 expressing cells

Country Status (6)

Country Link
US (2) US6071519A (en)
EP (1) EP0831917A2 (en)
JP (1) JPH11506915A (en)
AU (1) AU709988B2 (en)
CA (1) CA2222247A1 (en)
WO (1) WO1996040260A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506915A (en) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Immunotoxins specific for CD80 and CD86 expressing cells
JP2002540764A (en) * 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Humanized immunoglobulin reacting with B7 molecule and therapeutic method using the same
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1671741A (en) * 2002-06-21 2005-09-21 拜奥根Idec公司 Buffered formulations for concentrating antibodies and methods of use thereof
US7854752B2 (en) 2004-08-09 2010-12-21 Theken Spine, Llc System and method for dynamic skeletal stabilization
CN101679522A (en) * 2007-03-28 2010-03-24 拜奥根Idec公司 Modulation of tumor microenvironment
CN104203982B (en) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 Polypeptide construct and application thereof
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
US9758566B2 (en) * 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
KR101918456B1 (en) * 2015-12-15 2018-11-16 앱클론(주) Antibodies Capable of Binding Specifically to CD80 and CD86
KR101932408B1 (en) * 2018-07-04 2018-12-31 앱클론(주) Antibodies Capable of Binding Specifically to CD80 and CD86

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) * 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
WO1992000762A1 (en) * 1990-07-05 1992-01-23 Akzo N.V. Receptor directed-toxin conjugates
DE4205938A1 (en) * 1992-02-27 1993-09-02 Medac Klinische Spezialpraep New immuno-toxin contg. CD30 monoclonal antibody - is coupled to type 1 ribosome inactivating protein toxin, for selective elimination of CD30 cells, esp. treatment of Hodgkins disease
WO1994001547A2 (en) * 1992-07-09 1994-01-20 Cetus Oncology Corporation A method for generation of antibodies to cell surface molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
JPH11506915A (en) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Immunotoxins specific for CD80 and CD86 expressing cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) * 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
WO1992000762A1 (en) * 1990-07-05 1992-01-23 Akzo N.V. Receptor directed-toxin conjugates
DE4205938A1 (en) * 1992-02-27 1993-09-02 Medac Klinische Spezialpraep New immuno-toxin contg. CD30 monoclonal antibody - is coupled to type 1 ribosome inactivating protein toxin, for selective elimination of CD30 cells, esp. treatment of Hodgkins disease
WO1994001547A2 (en) * 1992-07-09 1994-01-20 Cetus Oncology Corporation A method for generation of antibodies to cell surface molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002021843 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002021842 *
KIYOSHI S. ET AL.: "AMELORIATION OF LETHAL MURINE GRAFT-VERSUS-HOST DISEASE BY THE TREATMENT WITH ANTI-CD80 AND -CD86 MOAB'S.", 9TH INTERNAT. CONGRESS OF IMMUNOLOGY, 23 July 1995 (1995-07-23) - 29 July 1995 (1995-07-29), SAN FRANCISCO, pages 427 *
VAN GOOL S.W.: "CD80 (B7-1) AND CD86 (B7-2): POTENTIAL TARGETS FOR IMMUNOTHERAPY?", RESEARCH IN IMMUNOLOGY, vol. 146, no. 3, pages 183 - 196, XP022228333, DOI: doi:10.1016/0923-2494(96)80256-2 *
VIJAY K. KUCHROO ET AL.: "B7-1 AND B7-2 COSTIMULATORY MOLECULES ACTIVATE DIFFERENTIALLY THE TH1/TH2 DEVELOPMENTAL PATHWAYS: APPLICATION TO AUTOIMMUNE DISEASE THERAPY", CELL, vol. 80, NA US, pages 707 - 718, XP002021840 *
VOOIJS W.C. ET AL.: "EVALUATION OF B7-1 AND B7-2 IMMUNOTOXINS AS POTENTIAL THERAPY FOR HODGKIN'S DISEASE.", BLOOD, vol. 86, no. 10, 1995, pages 826A, XP002021841 *

Also Published As

Publication number Publication date
EP0831917A2 (en) 1998-04-01
CA2222247A1 (en) 1996-12-19
US6346248B1 (en) 2002-02-12
JPH11506915A (en) 1999-06-22
WO1996040260A2 (en) 1996-12-19
US6071519A (en) 2000-06-06
AU6301696A (en) 1996-12-30
AU709988B2 (en) 1999-09-09

Similar Documents

Publication Publication Date Title
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
AU3070897A (en) Global financial services integration system and process
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
HK1044159A1 (en) Humanized antibodies to gamma-interferon
WO1995022258A3 (en) Isolation of lactoferrin from milk
AU1923895A (en) Computerized, multimedia, network, real time, interactive marketing and transactional system
WO1996040260A3 (en) Immunotoxins specific for cd80 and cd86 expressing cells
CA2290485A1 (en) Method for the production of non-immunogenic proteins
AU4612093A (en) Soluble ligands for CD40
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
HK1048831A1 (en) Human ctla-4 antibodies and their uses
ZA967389B (en) Method of forming improved apertured films, resultant apertured films, and absorbent products incorporating resultant apertured films.
AU1142097A (en) Device, system and method for implantation of filaments and particles in the body
HU9203370D0 (en) Humanized chimaeric anti-icam-1 antibodies and method for producing them
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
WO2000044389A3 (en) Method for preparing membrane vesicles
ZA977513B (en) Skin tanning compositions and method.
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
EP0100904A3 (en) Improved protocol for the treatment of graft versus host disease
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
AU5301196A (en) Method for stimulating an immune response
EP0396505A3 (en) Monoclonal antibodies specific for an immunoglobulin isotype
WO1998027966A3 (en) Encapsulated cells producing antibodies
HUP9802419A3 (en) Antigenic preparations, process for preparation and uses thereof
AU8132998A (en) Anti-cd40l immunotoxins for the treatment of diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2222247

Country of ref document: CA

Ref country code: CA

Ref document number: 2222247

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08973377

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 500165

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996921952

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996921952

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996921952

Country of ref document: EP